Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				NeuroendoUnit-4 NCT00495846

Last Modified: 10/11/2008 First Published: 9/9/2005


2.		Phase III Randomized Study of Octreotide in Patients With Cancer-Related Symptomatic Malignant Ascites

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NCCTG-N04C2 NCT00182754

Last Modified: 10/16/2008 First Published: 12/4/2007


3.		Phase III Randomized Study of Depot Octreotide Acetate and Interferon alfa-2b Versus Depot Octreotide Acetate and Bevacizumab in Patients With Unresectable Metastatic or Locally Advanced, High-Risk Neuroendocrine Carcinoid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				NCI				SWOG-S0518 S0518, NCT00569127


4.		Evaluation of Octreotide LAR in Prevention of Chemotherapy-Induced Diarrhea

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 to 70				Pharmaceutical / Industry				CSMS995AIC04 NCT00582426


5.		Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CSMS995ADE13 NCT00332969


6.		Sandostatin for Patients With Androgen Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				Other				UCSF055514 NCT00510224

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute